Clinical trial
Neoadjuvant Icotinib With Chemotherapy for Resectable Stage II-IIIB N2 EGFR Mutation-positive Lung Adenocarcinoma: A Phase II Study
NCT05132985 is registered in ClinicalTrials.gov with Liaoning Cancer Hospital & Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Neoadjuvant Icotinib With Chemotherapy for Resectable Stage II-IIIB N2 EGFR Mutation-positive Lung Adenocarcinoma: A Phase II Study
- Lead sponsor
- Liaoning Cancer Hospital & Institute
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- January 1, 2022
- Completion date
- January 1, 2028
- Enrollment
- 45 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
egf-r positive non-small cell lung cancer, nsclc